How to Help Your Patients Find Levemir in Stock: A Provider's Guide

Your Patients Need Levemir — Here's How to Help Them Find It

As Levemir (Insulin Detemir) moves toward full discontinuation, providers across endocrinology, internal medicine, and primary care are fielding an increasing number of calls from patients who can't fill their prescriptions. This guide offers practical, actionable steps you can take to help your patients maintain uninterrupted access to basal insulin — whether that means locating remaining Levemir stock or facilitating a smooth transition to an alternative.

For a broader clinical overview of the shortage and its implications, see our companion article: Levemir shortage: What providers and prescribers need to know in 2026.

Current Availability of Levemir

As of early 2026, Levemir supply continues to decline nationwide. Here's the current picture:

• Major chain pharmacies (CVS, Walgreens, Rite Aid) report limited to zero Levemir stock in most markets.
• Independent pharmacies may retain limited supply through alternative wholesale distributors.
• Specialty and mail-order pharmacies have inconsistent availability that changes weekly.
• Hospital pharmacies may have reserved stock for inpatient use but generally cannot dispense for outpatient prescriptions.

The key takeaway: Levemir is still available in some locations, but finding it requires active searching rather than passive ordering.

Why Patients Can't Find Levemir

Your patients may be confused about why their usual pharmacy suddenly can't fill a prescription they've been getting for years. Here are the factors you can share with them:

1. Manufacturer discontinuation: Novo Nordisk is permanently stopping production of Levemir. This is not a temporary supply disruption.
2. No biosimilar: There is no alternative manufacturer producing Insulin Detemir, unlike Insulin Glargine which has multiple biosimilar options.
3. Uneven distribution: Remaining inventory is distributed unevenly across the supply chain. Some pharmacies may receive a shipment one week and nothing the next.
4. Insurance formulary changes: Many plans have preemptively removed Levemir or placed it on higher tiers, making it harder for pharmacies to justify stocking it.

What Providers Can Do: 5 Actionable Steps

Step 1: Identify Patients Still on Levemir

Run a report in your EHR to identify all active patients with a Levemir prescription. Prioritize outreach to patients who:

• Have not been seen in the last 6 months
• Have upcoming refill dates
• Are in high-risk groups (pediatric, pregnant, elderly, type 1 diabetes)

Proactive outreach now prevents emergency calls later.

Step 2: Use Medfinder to Locate Stock

Medfinder for Providers offers real-time pharmacy stock data for Levemir and alternative insulins. You can:

• Search by patient zip code to find nearby pharmacies with Levemir in stock
• Identify which pharmacies carry specific alternative insulins
• Share search results directly with patients

Integrating a quick Medfinder check into your prescription workflow can save significant time for both your staff and your patients.

Step 3: Prescribe Alternatives Proactively

Rather than waiting for patients to run out of Levemir, consider proactively switching them to an available alternative. The main options:

• Insulin Glargine (Lantus, Basaglar, Semglee): Most common transition. Unit-for-unit starting dose from Levemir. Patients on twice-daily Levemir may consolidate to once-daily Glargine. Biosimilars are widely available and cost-effective ($150-$300/box).
• Insulin Degludec (Tresiba): Start at approximately 80% of total daily Levemir dose. Good option for patients with variable schedules or nocturnal hypoglycemia. More expensive ($400-$550/box) but covered by many plans.
• NPH Insulin (Humulin N, Novolin N): Budget-friendly option ($50-$150/vial). Requires twice-daily dosing. Best for cost-sensitive patients who can manage more frequent monitoring.

For detailed patient-facing information on alternatives, share our article on alternatives to Levemir.

Step 4: Write Bridge Prescriptions

For patients actively searching for Levemir, consider writing a bridge prescription for an alternative insulin that the patient can fill immediately. This ensures they are never without basal insulin, even if they continue looking for Levemir.

Communicate clearly to the patient that the bridge prescription is a safety net — not necessarily a permanent switch — while you work together on a long-term plan.

Step 5: Address Cost Barriers

When transitioning patients to a new insulin, cost can be a significant barrier. Proactive steps:

• Check the patient's insurance formulary for preferred basal insulins before prescribing
• Use Medfinder for Providers to compare availability and pricing
• Direct uninsured patients to manufacturer assistance programs (Novo Nordisk PAP for Tresiba: 1-866-310-7549; Lilly Insulin Value Program for Basaglar)
• Remind patients about the federal $35/month insulin cap under Medicare Part D
• Suggest discount cards (GoodRx, SingleCare) for patients without assistance program eligibility

For a patient-facing resource, share our article on saving money on Levemir and insulin alternatives.

Alternatives at a Glance

Here's a quick-reference comparison for the most common Levemir alternatives:

• Insulin Glargine (Basaglar/Semglee): Once daily, ~$150-$300/box, widely available, biosimilar
• Insulin Glargine (Lantus): Once daily, ~$300-$400/box, brand-name
• Insulin Degludec (Tresiba): Once daily (flexible timing), ~$400-$550/box, ultra-long acting
• NPH Insulin (Humulin N/Novolin N): Twice daily, ~$50-$150/vial, intermediate acting

Workflow Tips for Your Practice

Here are ways to streamline the Levemir transition across your patient panel:

• Create a templated EHR note for Levemir-to-alternative insulin transitions, including dose conversion, monitoring plan, and follow-up schedule.
• Set up a follow-up protocol — schedule a check-in (telehealth or phone) 1-2 weeks after the switch to review blood glucose logs and adjust doses.
• Train front-desk staff to handle patient calls about Levemir availability and direct them to Medfinder or schedule a provider visit for medication change.
• Batch transitions — if you have a large panel of Levemir patients, consider a dedicated clinic day or outreach campaign to transition patients proactively.
• Bookmark medfinder.com/providers for quick stock checks during patient encounters.

Final Thoughts

The Levemir discontinuation is an operational challenge, but with proactive planning, it's manageable. Identify your affected patients, start transitions early, use tools like Medfinder for Providers to locate stock and compare alternatives, and address cost barriers head-on.

The patients who will struggle most are those who don't learn about the discontinuation until they're at the pharmacy with an empty pen. By reaching out now, you can prevent gaps in therapy and ensure your patients maintain stable glycemic control through the transition.

For related resources to share with your patients, see:

• How to find Levemir in stock near you
• Levemir shortage update for patients
• What is Levemir: uses, dosage, and what you need to know